Pancreatic Cancer Research

ResearcherCalifornia NanoSystems InstituteNo recent work listed

Huan Meng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8844-3938; OpenAlex author ID A5100623489; NIH RePORTER profile ID 10936558. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 7)
Trials
0
Grants
1
Labs led
1
Collaborators
14
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper, 1 grant · 2020: 1 paper · 2021: 3 papers

Papers 11

  1. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Last author DOI 10.1002/advs.202002147↗
  2. Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. Last author DOI 10.1002/smll.202005993↗
  3. Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2021.121176↗
  4. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment. Last author DOI 10.1038/s41467-020-17996-7↗
  5. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery. Last author DOI 10.7150/thno.38587↗
  6. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Co-author DOI 10.1016/j.addr.2018.06.014↗
  7. Major effect of transcytosis on nano drug delivery to pancreatic cancer. Last author DOI 10.1080/23723556.2017.1335273↗
  8. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. Last author DOI 10.1172/jci92284↗
  9. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. Last author DOI 10.1021/acsnano.5b07781↗
  10. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. Co-author DOI 10.1021/acsnano.5b00510↗
  11. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. Co-author DOI 10.1021/nn404083m↗

Grants 1

  1. UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer U01CA198846↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. André E. Nel · 8 shared papers, 1 shared grant, 2013–2021 · strength 0.98
  2. Xiangsheng Liu · 9 shared papers, 2015–2021 · strength 0.89
  3. Timothy R. Donahue · 3 shared papers, 1 shared grant, 2016–2020 · strength 0.51
  4. Ying Chao Ji · 3 shared papers, 2020–2021 · strength 0.34
  5. Jeffrey I Zink · 1 shared paper, 1 shared grant, 2013–2019 · strength 0.31
  6. Zev A. Wainberg · 2 shared papers, 2017–2021 · strength 0.17
  7. Quan Zhou · 1 shared paper, 2021 · strength 0.12
  8. Haiping Jiang · 1 shared paper, 2021 · strength 0.12
  9. Liping Cao · 1 shared paper, 2021 · strength 0.12
  10. Youqing Shen · 1 shared paper, 2021 · strength 0.12
  11. Xiangrui Liu · 1 shared paper, 2021 · strength 0.12
  12. Liying Wang · 1 shared paper, 2021 · strength 0.12
  13. Juan Li · 1 shared paper, 2020 · strength 0.11
  14. Huiyu Liu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.